Skip to Main Content
Contribute Try STAT+ Today

Moderna is moving at unprecedented speed to develop a vaccine to prevent infection from the novel coronavirus. But the biotech’s soaring stock price is moving faster, which raises an important question: Are investors taking on too much risk?

Since late February, Moderna shares have more than tripled in value — making it one of the top-performing biotech stocks this year. On Monday, shares hit an all-time high of $66.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I used to subscribe to your service when you were at the street
    Since then I have bee out of biotech
    But I am considering getting back in
    Before I subscribe I would be interested in your comments Radius Rdus . Prior to 17 I sold at 55 but now it’s in the low teens ????
    Thank you

Comments are closed.